Journal
ONCOLOGIST
Volume 13, Issue 9, Pages 933-944Publisher
ALPHAMED PRESS
DOI: 10.1634/theoncologist.2008-0019
Keywords
Epidermal growth factor receptor; EGFR; Tyrosine kinase inhibitor; TKI; Erlotinib; Non-small cell lung cancer; NSCLC; Second-line therapy
Categories
Ask authors/readers for more resources
There has been intense investigation into the epidermal growth factor receptor ( EGFR) as a therapeutic target in the treatment of non-small cell lung cancer (NSCLC). Currently there are two EGFR tyrosine kinase inhibitors, erlotinib and gefitinib, approved for the treatment of advanced NSCLC. In a phase III trial (BR. 21), treatment with erlotinib resulted in a statistically significant improvement in overall survival in patients who had experienced progression after one or two previous chemotherapy treatments in comparison with best supportive care (BSC). In contrast, in the Iressa Survival Evaluation in Lung Cancer (ISEL) trial, treatment with gefitinib did not result in a statistically significant improvement in overall survival time in comparison with BSC in patients who had received one or two previous chemotherapy treatments and were refractory to or intolerant of the previous chemotherapy. After the results of the ISEL trial, the U. S. Food and Drug Administration restricted the use of gefitinib, and gefitinib was effectively removed from routine clinical
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available